Lantheus Medical Imaging parent Lantheus Holdings said its Pylarify AI prostate cancer software is now commercially available in the U.S.
The artificial intelligence (AI) software uses a deep-learning algorithm that has been trained and validated on more than 3,000 images. It allows healthcare professionals and researchers to perform standardized quantitative assessment of prostate-specific membrane antigen (PSMA) PET/CT images.
The FDA-cleared device can be utilized as a secure web cloud application or within the firewall of an institution on a local server. After it is deployed, the application can be integrated into an institution's existing clinical workflow, Lantheus said.
Syntermed is the first U.S. distributor of Pylarify AI.
